- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05143268
Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma (ACP-HN)
Impact of Acupuncture on Acute Dysphagia in Patients Treated With Radio-chemotherapy for Head and Neck Squamous Cell Carcinoma: a Randomized Phase 2 Study
Study Overview
Status
Conditions
Detailed Description
In order to attempt to reduce the impact of adverse effects produced by oncological treatments, cancer patients frequently turn to complementary integrative therapies.
Among them, acupuncture has been characterized by a growing role in cancer-related symptoms management in last 10 years.
After FDA approval for use as a medical device in 1996, the application of this technique in oncology has been on the rise in the Western countries.
By modulating brain regions involved in cognition and emotion, some degree of successful symptom management with acupuncture has been demonstrated in oncology In the context of head and neck cancer, the first application of acupuncture was related to chronic shoulder pain and dysfunction following neck dissection.
The primary objective of the study is to compare the effect of acupuncture and standard treatment on swallowing function assessed with MDADI scale (MD Anderson Dysphagia Inventory) 2 weeks after the end of RT (end of treatment, EoT).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Lorenzo Livi, Professor
- Phone Number: 0557947192
- Email: lorenzo.livi@unifi.it
Study Locations
-
-
-
Florence, Italy, 50134
- Recruiting
- Azienda Ospedaliero Universitaria Careggi
-
Contact:
- Noela Gori, Study Coordinator
- Phone Number: 0557947192
- Email: datamanager.ng.rt@sbsc.unifi.it
-
Florence, Italy, 50134
- Recruiting
- AOU Careggi Radiation Oncology Unit
-
Contact:
- Pierluigi Bonomo
- Phone Number: +390557947264
- Email: bonomop@aou-careggi.toscana.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- histologically-confirmed diagnosis of squamous cell carcinoma of the nasopharynx, oropharynx, hypopharynx and larynx or histologically-confirmed diagnosis of undifferentiated carcinoma of the nasopharynx
by judgement of the local investigator, indication for a DNST with curative intent, consisting of one of the 3 following options:
- radiotherapy alone
- cisplatin-based concomitant chemo-radiotherapy
- cetuximab-based concomitant bio-radiotherapy
- clinical stage of disease: II, III, IVA, IVB (according to TNM/AJCC 8th edition) for primary tumors of the larynx, hypopharynx and oropharynx (p16/HPV negative), provided that for stage II disease (cT2N0) the local investigator will prescribe an elective irradiation of regional lymph nodes
- clinical stage of disease: I, II, III (according to TNM/AJCC 8th edition) for primary tumors of the oropharynx (p16/HPV positive), provided that for stage I disease (cT1N0) the local investigator will prescribe an elective irradiation of regional lymph nodes
Exclusion Criteria:
- histologically-confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with HNSCC of unknown primary or non-squamous histologies
- metastatic disease
- gross total excision of both primary and nodal disease before index treatment
- surgical manipulation including therapeutic tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease
- prior radiotherapy to the head and neck region
- induction chemotherapy prior to radiotherapy
- prior use of acupuncture for SCCHN or for different indications
- prior allergic reaction or history of hypersensitivity to inox austenitic steel (Cr18Ni9)
- active or prior documented neurologic or rheumatologic disorder with a potential impact on the swallowing function (i.e: multiple sclerosis, amyotrophic lateral sclerosis, scleroderma)
- active process of severe skin infection in the neck contraindicating the execution of acupuncture in the opinion of the investigator
- severe baseline dysphagia documented by a MDADI scale (MD Anderson Dysphagia Inventory) composite score below 60
- any condition that, in the opinion of the investigator, would not require to encompass at least ipsilateral neck lymph nodes in the irradiation field
- any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
A
In the experimental arm (arm A), a total of 11 sessions of acupuncture will be performed on a weekly basis, spanning from 2 weeks before Radiotherapy start throughout 7 weeks of treatment, to 2 weeks after its completion.
Patients randomized to the experimental arm will receive acupuncture in addition to standard of care treatment, chosen by the treating multidisciplinary team in accordance with international guidelines.
|
B
In the standard arm (arm B), patients will be treated with standard of care treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary objective
Time Frame: two weeks after the end of treatment
|
Swallowing function assessed with MDADI scale (MD Anderson Dysphagia Inventory)
|
two weeks after the end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary objective n.1
Time Frame: 12 weeks after end of treatment
|
Swallowing function assessed with MDADI scale (MD Anderson Dysphagia Inventory)
|
12 weeks after end of treatment
|
Secondary objective n.2
Time Frame: 24 weeks after end of treatment
|
Swallowing function assessed with MDADI scale (MD Anderson Dysphagia Inventory)
|
24 weeks after end of treatment
|
Secondary objective n.3
Time Frame: 12 and 24 weeks after end of treatment
|
Patients' quality of life assessed with the EORTC QLQ-C30 and QLC-HN 43
|
12 and 24 weeks after end of treatment
|
Secondary objective n.4
Time Frame: maximum of 11 weekly sessions
|
Feasibility of acupuncture (percentage of completed acupuncture sessions out of planned per protocol)
|
maximum of 11 weekly sessions
|
Secondary objective n.5
Time Frame: 2 weeks after end of treatment
|
Incidence of moderate-severe dysphagia (>G2) assessed with CTCAE v. 5.0
|
2 weeks after end of treatment
|
Secondary objective n.6
Time Frame: 2 weeks after end of treatment
|
Incidence of moderate-severe adverse events (G3-G4) assessed with CTCAE v.5
|
2 weeks after end of treatment
|
Secondary objective n.7
Time Frame: 2 weeks after the end of treatment
|
Relative dose intensity of systemic therapy
|
2 weeks after the end of treatment
|
Secondary objective n.8
Time Frame: 2 weeks after end of treatment
|
Radiation interruptions
|
2 weeks after end of treatment
|
Secondary objective n.9
Time Frame: 2 weeks after end of treatment
|
Relative weight loss (percentage of weight loss compared with baseline value at start of therapy)
|
2 weeks after end of treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACP-HN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Xiang LuRecruitingHead and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell CarcinomaChina
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
National Taiwan University HospitalUnknownHead-and-Neck Squamous Cell CarcinomaTaiwan
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States